ClinicalTrials.gg
CompletedNCT03172325Updated Feb 2, 2021Results posted

Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA

A Phase 3 interventional study of Adalimumab and Methotrexate in Active Rheumatoid Arthritis, sponsored by Cinnagen. Completed at 10 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Cinnagen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Nov 2015, registered May 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
49th of 87
136 · median 160
Started
2015
with 7 others
Phase 3
36 of 87
1 open now
Registered
76th of 87
by date

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 49th largest by enrollment, is one of 8 that started in 2015, is one of 36 in phase 3, and was the 76th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis. Patients with the diagnosis of active Rheumatoid arthritis according to EULAR criteria (European League Against Rheumatism) aged between 18 to 75 years will be included. This study is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active-controlled non-inferiority clinical trial. The eligible patients are randomized in a 1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs will be administered to each patient subcutaneously along with methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.

The primary objective of the study is to compare the efficacy of test- adalimumab (CinnoRA®) and the reference adalimumab (Humira®) in patients with moderately to severely active rheumatoid arthritis regarding the evaluation of EULAR criteria based on Disease activity score (DAS).

The secondary objectives of this study are:

  • To further compare the efficacy of test- adalimumab to reference adalimumab
  • To assess the safety of test- adalimumab compared to reference adalimumab
Read the detailed description

The purpose of this study is to compare the efficacy and safety of Adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active rheumatoid arthritis. Patients with the diagnosis of active rheumatoid arthritis according to EULAR criteria (European League Against Rheumatism) aged between 18 to 75 years will be included. This study is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active-controlled non-inferiority clinical trial. The eligible patients will be randomized in a 1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs will be administered to each patient subcutaneously along with methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.

Physical examinations, vital signs, disease activity, and laboratory parameters will be evaluated for patients at baseline and 3 and 6-month visits. The incidence of adverse events at each visit will be recorded based on patients' reports, vital signs, physical examinations, and laboratory tests.

The trial is reviewed by food and drug administration of Iran. The protocol, case report form (CRF), information for patients, and informed consent form are submitted to the ethics committees responsible for review and approval purposes, according to national regulatory guidelines.

In this study, no patient will be recruited without an informed consent form. All the informed consent forms which will be signed by the patients will have two copies so that patients can receive a copy of it.

Determination of sample size:

The outcome measures of this study are changes in composite scores defined by the European League against Rheumatism (EULAR) and the American College of Rheumatology criterions. The CinnoRA® group proportion is assumed to be 0.7100 under the null hypothesis of inferiority. If the response rate of CinnoRA® is at most 18% worse than Humira® (δ = -0.18) (non-inferiority margin), it will be considered to be non-inferior. Sample size 64 in both Humira and CinnoRA® groups yields 90% power to detect non-inferiority margin. The significance level of the test is targeted at 0.0250 (The significance level actually achieved by this design is 0.0284).

DATA QUALITY ASSURANCE:

CinnaGen Company conducts clinical trials according to procedures that incorporate the ethical principles of good clinical practice (GCP). Accurate and reliable data collection is assured by verification and cross-check of the CRFs against the patient's records by clinical monitors, and the maintenance of a drug-dispensing log by the center.

Principle and coordinating investigators, contract research organization (CRO) coordinators and sponsor personnel attend the investigator meetings, and at the end, they receive a GCP certificate.

CRO coordinators and one sponsor attend the Site Initiation Visit (SIV) meetings. Protocol and GCP principles are reviewed by coordinating investigator of each site, and also the needed information for completing CRF and Trial Master File (TMF) forms are explained.

Monitoring by CRO will be performed in 30% and 70% of study progress and at the end of the study. In the monitoring sessions, some sponsor personnel will audit the process. During the monitoring process, the CRO coordinator will check all CRFs and will confirm them to the source documents, and for required cases, the query form will be filled out.

The temperature of the refrigerator which containing the medicines will be checked and recorded by a data logger which will be checked repeatedly by an auditor.

TMF will be checked by CRO coordinator, and it will be rechecked by an auditor. Drug accountability data and information about the proper time for patients' injections will be checked by CRO coordinator and rechecked by sponsor personnel.

After monitoring, problems will be reported by monitor and auditor to the trial centers.

Blinding:

The study will be double-blind. The Subjects and those who conduct the study will be unaware of the state of the patient with regard to the treatment assignments. For this purpose, subjects will be blinded by using a prefilled syringe of Adalimumab, which is quite similar to each other. The injection method, injection syringes, and cartridges are totally the same in both groups. To blind those who conduct the study, the person who delivers or checks the study drug will be different from those who examine the patients. All drugs packages will be identified by unique numbers (manufacture code). Finally, the randomization table will be concealed from research staff by using opaque sealed envelopes.

It should be noted that CRO personnel who enter data into CRF and database and also the sponsor personnel who monitor data entry will be blinded. The study will be double-blind, and situations that might warrant breaking the code are defined in the protocol and include serious adverse events.

Handling of Dropouts or Missing Data:

Since the number of patients who will participate in this clinical trial is limited and small, the investigator can't perform missing imputation analysis and do statistical analysis on those patients who are completed the entire study. However, analyses of the adverse events will be performed on patients who entered the study.

In this study, patients with at least one adverse event will be included in the report. For each adverse event, data will be summarized using frequencies and percentages and then classifies according to the body system. They will be reported in the form of incidence rate. In other words, patients with any number of Adverse Events will be counted only once in this calculation.

03

Conditions studied

  • Active Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-75 years at the time of signing the form.
  • Have been diagnosed as having active rheumatoid arthritis (RA) according to The European League Against Rheumatism criteria
  • moderately to severely active RA for at least six months
  • Patients who have an inadequate response to the treatment with the usual non-biological regimen for at least 12 weeks according to their investigator judgment.
  • Ability to comprehend and willingness to sign the Informed Consent Form for this study.

Exclusion criteria

Exclusion Criteria:

  • Tuberculosis patient or latent tuberculosis patient (PPD >5mm or abnormal Chest X-ray)
  • Have been treated previously with any biological agents including any tumor necrosis factor inhibitors (including ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), SIMPONI® (golimumab), or Adalimumab).
  • Have a known to human immunoglobulin proteins or other components of Humira or test- Adalimumab
  • Women who are pregnant, breastfeeding or planning to become pregnant during the study
  • Have a positive serological test for or or have a known history of infection with (HIV) of the past three months.
  • Physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound)
  • Have had a serious infection or have been treated with intravenous antibiotics for an infection within eight weeks or oral antibiotics within two weeks prior to screening
  • Have a history of chronic or recurrent infection
  • (AST) or alanine aminotransferase (ALT) > two times .
  • \<8.5 g/dL.
  • \<125,000/µL.
  • Leukocyte count \<3500/µL.
  • Serum Creatinine>2 mg/dl
  • Concomitant use of Prednisolone > 10 mg/day and NSAIDs
  • Treatment with intravenous, intramuscular, intra-articular and oral within four weeks prior to Day 1 (prednisolone, more than 7.5 mg/daily)
  • Ever used RITUXAN® (rituximab), IMURAN® (azathioprine), or PURINETHOL® (mercaptopurine, 6-MP).
  • Have any of the following conditions:

    1. History of congestive heart failure.
    2. History of acute myocardial infarction or unstable angina within the previous 12 months prior to Screening.
    3. History of demyelinating disorders (e.g., MS)
    4. History of multiple sclerosis
    5. History of any within the previous five years prior to Screening.
    6. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    CinnaGen adalimumab

    CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.

    Drug: Adalimumab · Drug: Methotrexate · Drug: Folic Acid · Drug: Prednisolone

  • Active comparator
    AbbVie adalimumab

    Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.

    Drug: Adalimumab · Drug: Methotrexate · Drug: Folic Acid · Drug: Prednisolone

Interventions

  • 40 mg Adalimumab every other week is administered subcutaneously to all the patients.

  • 15 mg Methotrexate is weekly administered to all the patients.

  • At least 1 mg Folic acid is daily administered to all the patients.

  • 7.5 mg Prednisolone is daily administered to all the patients.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24

    The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula: DAS28-ESR= (0.56\*√(Tender Joint Count)+0.28\*√(Swollen Joint Count)+0.7\*ln(ESR)+0.014\*(global health))

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24

    ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.

    Time frame: Week 24

  2. Health Assessment Questionnaire (HAQ) Disability Index at Week 24.

    Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.

    Time frame: Week 24

  3. The Incidence of Adverse Events

    The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.

    Time frame: From the time of first treatment up to the last dose of study treatment; 24 weeks.

  4. Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)

    Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.

    Time frame: Week 24

07

Results

Posted Feb 2, 2021

Participant flow

Participant flow — Overall Study
MilestoneCinnaGen AdalimumabAbbVie Adalimumab
Started6868
Completed6464
Not completed44
Withdrew: Adverse event23
Withdrew: Positive ppd10
Withdrew: Poor compliance11

Outcome measures

PrimaryPercentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24

The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula: DAS28-ESR= (0.56\*√(Tender Joint Count)+0.28\*√(Swollen Joint Count)+0.7\*ln(ESR)+0.014\*(global health))

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24
percentage of participantsCinnaGen AdalimumabAbbVie Adalimumab
Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 246363
SecondaryPercentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24

ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24
percentage of participantsCinnaGen AdalimumabAbbVie Adalimumab
Percentage of Patients achieving ACR209289
Percentage of Patients achieving ACR507775
Percentage of Patients achieving ACR704753
SecondaryHealth Assessment Questionnaire (HAQ) Disability Index at Week 24.

Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.

Time frame:
Week 24
Reported as:
Median · score on a scale
Health Assessment Questionnaire (HAQ) Disability Index at Week 24.
score on a scaleCinnaGen AdalimumabAbbVie Adalimumab
Health Assessment Questionnaire (HAQ) Disability Index at Week 24.0.25 (0 to 0.63)0.19 (0 to 0.63)
SecondaryThe Incidence of Adverse Events

The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.

Time frame:
From the time of first treatment up to the last dose of study treatment; 24 weeks.
Reported as:
Count of participants · Participants
The Incidence of Adverse Events
ParticipantsCinnaGen AdalimumabAbbVie Adalimumab
The Incidence of Adverse Events2330
SecondaryImmunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)

Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)
ParticipantsCinnaGen AdalimumabAbbVie Adalimumab
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)52

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CinnaGen Adalimumab1/68 (1.5%)2/68 (2.9%)23/68 (33.8%)
AbbVie Adalimumab0/68 (0%)1/68 (1.5%)30/68 (44.1%)
Most frequent serious events
Most frequent serious events
EventCinnaGen AdalimumabAbbVie Adalimumab
Peritoneal tuberculosisInfections and infestations1/680/68
PneumoniaInfections and infestations1/681/68
Most frequent other events
Showing 10 of 28
Most frequent other events
EventCinnaGen AdalimumabAbbVie Adalimumab
Injection site reactionGeneral disorders6/6812/68
Respiratory infectionInfections and infestations2/687/68
SinusitisInfections and infestations1/684/68
Flu-like symptomsGeneral disorders3/684/68
NauseaGastrointestinal disorders4/682/68
HeadacheNervous system disorders4/684/68
RashSkin and subcutaneous tissue disorders2/683/68
ArthralgiaMusculoskeletal and connective tissue disorders1/683/68
UrticariaSkin and subcutaneous tissue disorders0/682/68
Abdominal painGastrointestinal disorders2/681/68

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CinnaGen AdalimumabAbbVie AdalimumabTotal
<=18 years000
Between 18 and 65 years5963122
>=65 years9514
Age, Continuous
Age, Continuous(years)CinnaGen AdalimumabAbbVie AdalimumabTotal
Mean48.29 ± 12.7247.59 ± 11.4847.94 ± 12.08
Sex: Female, Male
Sex: Female, Male(Participants)CinnaGen AdalimumabAbbVie AdalimumabTotal
Female5860118
Male10818
Region of Enrollment
Region of Enrollment(Participants)CinnaGen AdalimumabAbbVie AdalimumabTotal
Iran6868136
Patient assessment of pain
Patient assessment of pain(units on a scale)CinnaGen AdalimumabAbbVie AdalimumabTotal
Mean67.21 ± 23.5170.22 ± 21.9368.71 ± 22.70
Physician's global assessment of disease activity
Physician's global assessment of disease activity(units on a scale)CinnaGen AdalimumabAbbVie AdalimumabTotal
Mean68.97 ± 17.3870.44 ± 17.6869.71 ± 17.48
Patient global assessment of disease activity
Patient global assessment of disease activity(units on a scale)CinnaGen AdalimumabAbbVie AdalimumabTotal
Mean70.15 ± 20.3570.74 ± 22.2170.44 ± 21.23
Swollen joint count, 28 joints
Swollen joint count, 28 joints(Swollen joints)CinnaGen AdalimumabAbbVie AdalimumabTotal
Mean9.96 ± 7.399.46 ± 6.989.71 ± 7.17

5 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • Alzahra Hospital
    Isfahan, Iran, Islamic Republic of
  • Besat 4 Clinic
    Kerman, Iran, Islamic Republic of
  • Ghaem Hospital
    Mashhad, Iran, Islamic Republic of
  • Razi Hospital
    Rasht, Iran, Islamic Republic of
  • Imam Ali Clinic
    Shahr-e kord, Iran, Islamic Republic of
  • Hafez Hospital
    Shiraz, Iran, Islamic Republic of
  • Noor Medical Complex
    Tabriz, Iran, Islamic Republic of
  • Imam Reza Hospital (501 Artesh)
    Tehran, Iran, Islamic Republic of
  • Iran Rheumatism Center
    Tehran, Iran, Islamic Republic of
  • Loghman Hakim Hospital
    Tehran, Iran, Islamic Republic of
09

References and documents

Publications

  • McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8;365(23):2205-19. doi: 10.1056/NEJMra1004965. No abstract available. PubMed 22150039 ↗
  • den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, Binder C, Fenner H, Bankmann Y, Velagapudi R, Kempeni J, Kupper H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002 Nov;29(11):2288-98. PubMed 12415583 ↗
  • Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. No abstract available. PubMed 22473917 ↗
  • Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004 May;50(5):1400-11. doi: 10.1002/art.20217. PubMed 15146409 ↗
  • Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003 Dec;30(12):2563-71. PubMed 14719195 ↗
  • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan;48(1):35-45. doi: 10.1002/art.10697. Erratum In: Arthritis Rheum. 2003 Mar;48(3):855. PubMed 12528101 ↗
  • Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727-35. doi: 10.1002/art.1780380602. PubMed 7779114 ↗
  • Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002 May;301(2):418-26. doi: 10.1124/jpet.301.2.418. PubMed 11961039 ↗
  • Khan MOA, Mohiuddin E, Usmanghani K, Hannan A, Akram M, Shah SA, et al. Clinical evaluation of herbal medicines for the treatment of rheumatoid arthritis. Pak J Nutr. 2011;10(1):51-3.
  • Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine 18E Vol 2 EB: McGraw Hill Professional; 2012.
  • Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006 Dec;36(3):182-8. doi: 10.1016/j.semarthrit.2006.08.006. Epub 2006 Oct 11. PubMed 17045630 ↗
  • Yood RA, Guidelines ACoRSoRA. Guidelines for the management of rheumatoid arthritis: 2002 update. 2002.
  • Lee WY, Chen HY, Chen KC, Chen CY. Treatment of rheumatoid arthritis with traditional chinese medicine. Biomed Res Int. 2014;2014:528018. doi: 10.1155/2014/528018. Epub 2014 Jun 4. PubMed 24991562 ↗
  • Weinblatt ME, Schiff M, Valente R, van der Heijde D, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 2013 Jan;65(1):28-38. doi: 10.1002/art.37711. PubMed 23169319 ↗
  • Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, Aranda R, Becker JC, Qi K, Dougados M. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol. 2009 Apr;36(4):736-42. doi: 10.3899/jrheum.080813. Epub 2009 Feb 27. PubMed 19273451 ↗
  • Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. BMC Musculoskelet Disord. 2014 Dec 23;15:452. doi: 10.1186/1471-2474-15-452. PubMed 25539805 ↗
  • Hallikainen A, Vartiainen T. Food control surveys of polychlorinated dibenzo-p-dioxins and dibenzofurans and intake estimates. Food Addit Contam. 1997 May-Jun;14(4):355-66. doi: 10.1080/02652039709374538. PubMed 9205564 ↗
  • Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2003;(4):CD004525. doi: 10.1002/14651858.CD004525. PubMed 14584021 ↗
  • Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh SG, Soroush M, Ahmadzadeh A, Nazarinia MA, Mousavi M, Karimzadeh H, Shakibi MR, Rezaieyazdi Z, Sahebari M, Hajiabbasi A, Ebrahimi AA, Mahjourian N, Rashti AM. A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA(R)) to the reference product (Humira(R)) in patients with active rheumatoid arthritis. Arthritis Res Ther. 2017 Jul 20;19(1):168. doi: 10.1186/s13075-017-1371-4. PubMed 28728599 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Aug 2016, 8 months.

Results were first posted in Feb 2021, 4 years 5 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 8 months is below that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
Jun 1, 2017
StartActual
Nov 18, 2015
Primary completionActual
Aug 17, 2016
CompletionActual
Jan 4, 2017
Results first posted
Feb 2, 2021
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03172325
Lead sponsor
Cinnagen
Responsible party
Sponsor
First posted
Jun 1, 2017
Start date
Nov 18, 2015
Primary completion
Aug 17, 2016
Completion
Jan 4, 2017
Results posted
Feb 2, 2021
Last update
Feb 2, 2021

Study contacts

Ahmadreza Jamshidi, Professor
principal investigator · Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion